Patient-level outcomes for all subjects finishing the study
| Subject ID . | Site . | OL control . | CLC . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| BG (mmol/L) . | % Target . | # Hypo . | LBGI . | BG (mmol/L) . | % Target . | # Hypo . | LBGI . | ||||
| Mean . | SD . | Mean . | SD . | ||||||||
| 23101 | 1 | 6.92 | 1.52 | 98.00 | 3 | 1.27 | 8.31 | 2.13 | 76.60 | 1 | 0.44 |
| 23102 | 1 | 6.50 | 1.67 | 93.91 | 2 | 1.58 | 6.81 | 2.04 | 87.72 | 1 | 1.48 |
| 23104 | 1 | 8.48 | 2.62 | 70.96 | 0 | 0.71 | 7.64 | 1.88 | 87.50 | 1 | 0.74 |
| 23105 | 1 | 8.48 | 2.49 | 71.56 | 4 | 1.32 | 8.56 | 2.45 | 65.19 | 2 | 0.63 |
| 23106 | 1 | 7.85 | 2.48 | 77.60 | 3 | 1.72 | 9.23 | 2.37 | 60.85 | 5 | 0.57 |
| 23202 | 2 | 7.60 | 2.49 | 74.19 | 4 | 2.27 | 8.05 | 2.22 | 82.09 | 0 | 0.41 |
| 23203 | 2 | 6.70 | 3.27 | 88.15 | 9 | 2.95 | 6.07 | 1.79 | 88.47 | 4 | 3.08 |
| 23204 | 2 | 7.40 | 2.61 | 79.67 | 3 | 1.70 | 8.76 | 2.50 | 78.37 | 3 | 0.29 |
| 23301 | 3 | 9.21 | 2.37 | 68.09 | 2 | 0.46 | 10.02 | 3.59 | 62.94 | 0 | 0.19 |
| 23302 | 3 | 11.69 | 2.51 | 22.17 | 1 | 0.14 | 9.98 | 2.32 | 49.89 | 1 | 0.12 |
| 23303 | 3 | 9.14 | 2.47 | 49.54 | 2 | 0.64 | 10.00 | 2.61 | 49.01 | 2 | 0.31 |
| 23304 | 3 | 13.05 | 3.60 | 20.59 | 2 | 0.09 | 13.36 | 3.18 | 12.25 | 1 | 0.02 |
| 23305 | 3 | 8.05 | 2.53 | 78.30 | 5 | 1.22 | 9.20 | 2.91 | 60.74 | 0 | 0.77 |
| 23401 | 4 | 9.05 | 2.26 | 65.68 | 1 | 0.18 | 8.94 | 2.85 | 67.44 | 0 | 0.44 |
| 23402 | 4 | 9.59 | 2.35 | 61.36 | 1 | 0.39 | 9.18 | 3.24 | 67.34 | 0 | 0.64 |
| 23403 | 4 | 7.50 | 1.97 | 86.13 | 1 | 1.16 | 9.70 | 2.75 | 61.32 | 0 | 0.27 |
| 23404 | 4 | 6.59 | 1.77 | 93.83 | 0 | 1.52 | 7.95 | 2.11 | 80.05 | 1 | 1.17 |
| 23405 | 4 | 8.27 | 2.89 | 73.62 | 0 | 0.83 | 9.52 | 1.92 | 52.65 | 0 | 0.02 |
| Subject ID . | Site . | OL control . | CLC . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| BG (mmol/L) . | % Target . | # Hypo . | LBGI . | BG (mmol/L) . | % Target . | # Hypo . | LBGI . | ||||
| Mean . | SD . | Mean . | SD . | ||||||||
| 23101 | 1 | 6.92 | 1.52 | 98.00 | 3 | 1.27 | 8.31 | 2.13 | 76.60 | 1 | 0.44 |
| 23102 | 1 | 6.50 | 1.67 | 93.91 | 2 | 1.58 | 6.81 | 2.04 | 87.72 | 1 | 1.48 |
| 23104 | 1 | 8.48 | 2.62 | 70.96 | 0 | 0.71 | 7.64 | 1.88 | 87.50 | 1 | 0.74 |
| 23105 | 1 | 8.48 | 2.49 | 71.56 | 4 | 1.32 | 8.56 | 2.45 | 65.19 | 2 | 0.63 |
| 23106 | 1 | 7.85 | 2.48 | 77.60 | 3 | 1.72 | 9.23 | 2.37 | 60.85 | 5 | 0.57 |
| 23202 | 2 | 7.60 | 2.49 | 74.19 | 4 | 2.27 | 8.05 | 2.22 | 82.09 | 0 | 0.41 |
| 23203 | 2 | 6.70 | 3.27 | 88.15 | 9 | 2.95 | 6.07 | 1.79 | 88.47 | 4 | 3.08 |
| 23204 | 2 | 7.40 | 2.61 | 79.67 | 3 | 1.70 | 8.76 | 2.50 | 78.37 | 3 | 0.29 |
| 23301 | 3 | 9.21 | 2.37 | 68.09 | 2 | 0.46 | 10.02 | 3.59 | 62.94 | 0 | 0.19 |
| 23302 | 3 | 11.69 | 2.51 | 22.17 | 1 | 0.14 | 9.98 | 2.32 | 49.89 | 1 | 0.12 |
| 23303 | 3 | 9.14 | 2.47 | 49.54 | 2 | 0.64 | 10.00 | 2.61 | 49.01 | 2 | 0.31 |
| 23304 | 3 | 13.05 | 3.60 | 20.59 | 2 | 0.09 | 13.36 | 3.18 | 12.25 | 1 | 0.02 |
| 23305 | 3 | 8.05 | 2.53 | 78.30 | 5 | 1.22 | 9.20 | 2.91 | 60.74 | 0 | 0.77 |
| 23401 | 4 | 9.05 | 2.26 | 65.68 | 1 | 0.18 | 8.94 | 2.85 | 67.44 | 0 | 0.44 |
| 23402 | 4 | 9.59 | 2.35 | 61.36 | 1 | 0.39 | 9.18 | 3.24 | 67.34 | 0 | 0.64 |
| 23403 | 4 | 7.50 | 1.97 | 86.13 | 1 | 1.16 | 9.70 | 2.75 | 61.32 | 0 | 0.27 |
| 23404 | 4 | 6.59 | 1.77 | 93.83 | 0 | 1.52 | 7.95 | 2.11 | 80.05 | 1 | 1.17 |
| 23405 | 4 | 8.27 | 2.89 | 73.62 | 0 | 0.83 | 9.52 | 1.92 | 52.65 | 0 | 0.02 |
Site 1, UVA; site 2, SDRI; site 3, Padova; site 4, Montpellier; % target, percentage of time within the target range of 3.9–10 mmol/L; # hypo, number of hypoglycemic episodes requiring treatment.